Advertisement
CANF vs ICU
Which Stock Would AI Choose? Can-Fite BioPharma (CANF) vs. SeaStar Medical (ICU) Stock Comparison
Key Takeaways
- CANF is a clinical-stage Israeli biotech advancing small-molecule drug candidates in oncology and inflammatory disease, while ICU is a commercial-stage medical device company focused on treating hyperinflammation in critically ill patients.
- Both names are small-cap, cash-constrained healthcare companies that recently announced dilutive warrant-exercise financings, a shared source of near-term share-price pressure.
- CANF has been driven by clinical catalysts, including positive Phase 2a pancreatic cancer data for its lead liver drug Namodenoson.
- ICU combines a modest but growing commercial revenue stream (its QUELIMMUNE pediatric therapy) with a pivotal adult trial and recent reimbursement code updates.
- Their relative performance reflects very different risk profiles: clinical binary events versus early-stage commercialization and regulatory execution.
Introduction
Investors screening small-cap healthcare names frequently encounter two very different value propositions in CANF (Can-Fite BioPharma Ltd.) and ICU (SeaStar Medical Holding Corporation). One is a pre-revenue drug developer, the other a commercial-stage medical device firm. Both, however, operate in high-need medical markets and have shown outsized share-price volatility in recent weeks, driven by clinical readouts, financing events, and shifting market sentiment. This stock comparison examines their businesses, recent relative performance, and market positioning to help traders and investors assess how these two companies stack up in the current environment.
CANF Overview and Recent Performance
CANF, or Can-Fite BioPharma, is a clinical-stage biotechnology company based in Israel that develops proprietary small-molecule drugs targeting cancer, liver disease, and inflammatory conditions. Its lead candidates include Piclidenoson (in late-stage development for psoriasis) and Namodenoson, which is being evaluated for hepatocellular carcinoma (HCC, a form of liver cancer), metabolic dysfunction-associated steatohepatitis (MASH, a liver disease), and pancreatic cancer.
Recent market activity has centered on the company's clinical pipeline. In recent weeks, CANF reported that its Phase 2a pancreatic cancer study of Namodenoson met its primary safety endpoint and demonstrated durable overall survival outcomes, prompting plans to advance the drug into a Phase 2b combination study with chemotherapy. That catalyst drove a sharp single-session rally in the stock. In contrast, the company also announced the exercise of outstanding warrants for roughly $4.0 million in gross proceeds at a reduced exercise price, a dilutive financing that pressured the share price. This combination of clinical upside and financing overhang has defined sentiment around the name.
ICU Overview and Recent Performance
ICU, or SeaStar Medical Holding Corporation, is a commercial-stage healthcare company developing the Selective Cytopheretic Device (SCD), a therapy designed to calm overactive immune cells and reduce destructive hyperinflammation in critically ill patients. Its first commercial product, QUELIMMUNE, was approved in 2024 by the U.S. Food and Drug Administration (FDA) as the only approved treatment for life-threatening acute kidney injury (AKI) due to sepsis in certain pediatric patients.
In recent weeks, ICU has advanced on several fronts: it announced that new ICD-10-PCS billing codes became available for its SCD therapy for AKI, a step that can streamline hospital reimbursement and expand access, and it presented late-breaking data at ASN Kidney Week 2026. The company is also enrolling the NEUTRALIZE-AKI pivotal trial in adults. At the same time, the stock has experienced meaningful volatility, including a notable single-session decline, and the company separately announced the exercise of warrants for approximately $3.3 million in gross proceeds. As with CANF, financing-driven dilution remains a key consideration for investors.
Trending AI Robots
For traders seeking a more systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group earns a place in the Trending AI Robots section — those judged best-suited to current market conditions. These bots vary widely in trading style, strategy, timeframe, historical performance, and the specific set of tickers they monitor, so no two are alike. Whether you prefer short-term momentum, swing, or longer-horizon approaches, exploring the Trending AI Robots can help you identify automated strategies aligned with your own market outlook.
Head-to-Head Comparison
The most fundamental contrast between these two companies is business model. CANF is pre-revenue and its valuation hinges almost entirely on clinical trial outcomes and regulatory milestones — binary events that can produce dramatic single-day moves in either direction. Its growth drivers are pipeline-centric, including the potential advancement of Namodenoson in pancreatic cancer and continued progress in HCC and MASH.
ICU, by contrast, already generates product revenue from QUELIMMUNE, though the amounts remain small relative to its operating losses. Its growth drivers include expanding adoption at children's hospitals, the new billing codes, and the pivotal NEUTRALIZE-AKI adult trial. Sector exposure also differs: CANF sits squarely in clinical-stage biotechnology, while ICU spans medical devices and critical-care therapeutics. On risk, both face dilution from warrant exercises and capital raises, but CANF carries higher clinical binary risk, whereas ICU's risk is more weighted toward commercialization execution and trial enrollment. Market sentiment has been volatile for both, though for different catalysts.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view ICU as offering relatively more stable positioning in the current environment, given its existing FDA-approved product, an established — if modest — revenue base, and incremental catalysts such as new reimbursement codes and an advancing pivotal trial. CANF presents higher-momentum, higher-uncertainty characteristics tied to clinical data and financing. Because trend consistency and stability tend to weigh favorably in AI-driven analysis, the balance of evidence may lean toward ICU, though CANF's clinical catalysts could justify greater upside potential for risk-tolerant traders. As always, such assessments are probabilistic rather than definitive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and ICU is a Hold.
CANF's Indicator enters downward trend
The Aroon Indicator for CANF entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 328 similar instances where the Aroon Indicator formed such a pattern. In 284 of the 328 cases the stock moved lower. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANF as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, 35 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 69 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for CANF just turned positive on October 19, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 154 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.834) is normal, around the industry mean (2.988). P/E Ratio (-0.407) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ICU sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ICU moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 34 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ICU broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 147 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 83 of 147 cases where ICU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.252) is normal, around the industry mean (2.988). P/E Ratio (-1.677) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CANF | ||
|---|---|---|
OUTLOOK RATING 1..100 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | |
P/E GROWTH RATING 1..100 | 11 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CANF | ICU | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 88% |
| Advances ODDS (%) | 22 days ago 78% | 11 days ago 81% |
| Declines ODDS (%) | 7 days ago 87% | 9 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CANF’s FA Score shows that 1 FA rating(s) are green while ICU’s FA Score has 1 green FA rating(s).
- CANF’s FA Score: 1 green, 4 red.
- ICU’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CANF’s TA Score shows that 5 TA indicator(s) are bullish while ICU’s TA Score has 3 bullish TA indicator(s).
- CANF’s TA Score: 5 bullish, 3 bearish.
- ICU’s TA Score: 3 bullish, 8 bearish.
Price Growth
CANF (@Biotechnology) experienced а -2.09% price change this week, while ICU (@Biotechnology) price change was +5.32% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
ICU is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -0.02% | ||
| GNPX - CANF | 93% Closely correlated | -3.76% | ||
| ICU - CANF | 91% Closely correlated | +3.93% | ||
| MLEC - CANF | 89% Closely correlated | +3.75% | ||
| LONA - CANF | 78% Closely correlated | +7.59% | ||
| LNAI - CANF | 72% Closely correlated | +0.58% | ||
More | ||||
ICU and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To ICU | 1D Price Change % | ||
|---|---|---|---|---|
| ICU | 100% | +3.93% | ||
| CANF - ICU | 93% Closely correlated | -0.02% | ||
| APVO - ICU | 85% Closely correlated | -0.93% | ||
| GNPX - ICU | 82% Closely correlated | -3.76% | ||
| TNXP - ICU | 77% Closely correlated | -6.06% | ||
| LONA - ICU | 62% Loosely correlated | +7.59% | ||
More | ||||